210 related articles for article (PubMed ID: 35650124)
41. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
42. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
43. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
[TBL] [Abstract][Full Text] [Related]
44. Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report.
Arai T; Mukai S; Kazama R; Ogawa Y; Nishida K; Hatanaka K; Gohma I
J Infect Chemother; 2022 Jun; 28(6):810-813. PubMed ID: 35115239
[TBL] [Abstract][Full Text] [Related]
45. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
46. Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail.
Drouin AC; Theberge MW; Liu SY; Smither AR; Flaherty SM; Zeller M; Geba GP; Reynaud P; Rothwell WB; Luk AP; Tian D; Boisen ML; Branco LM; Andersen KG; Robinson JE; Garry RF; Fusco DN
Viruses; 2021 Jun; 13(7):. PubMed ID: 34201591
[TBL] [Abstract][Full Text] [Related]
47. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
48. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
[TBL] [Abstract][Full Text] [Related]
49. Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
Sharman JP; Burke JM; Yimer HA; Boxer MA; Babu S; Li J; Mun Y; Danilov AV;
Leuk Lymphoma; 2021 Apr; 62(4):791-800. PubMed ID: 33243049
[TBL] [Abstract][Full Text] [Related]
50. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Pott C; Sehn LH; Belada D; Gribben J; Hoster E; Kahl B; Kehden B; Nicolas-Virelizier E; Spielewoy N; Fingerle-Rowson G; Harbron C; Mundt K; Wassner-Fritsch E; Cheson BD
Leukemia; 2020 Feb; 34(2):522-532. PubMed ID: 31462735
[TBL] [Abstract][Full Text] [Related]
51. [Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
Zhao F; Cheng LL; Zheng Z; Zhang MC; Cheng S; Xu PP; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):513-517. PubMed ID: 35968596
[No Abstract] [Full Text] [Related]
52. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient.
Nakajima Y; Ogai A; Furukawa K; Arai R; Anan R; Nakano Y; Kurihara Y; Shimizu H; Misaki T; Okabe N
J Infect Chemother; 2021 Feb; 27(2):387-389. PubMed ID: 33328135
[TBL] [Abstract][Full Text] [Related]
53. Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma.
Hamlin PA
Lancet Oncol; 2016 Aug; 17(8):1023-1025. PubMed ID: 27345637
[No Abstract] [Full Text] [Related]
54. Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.
Farris M; Hughes RT; Lamar Z; Soike MH; Menke JR; Ohgami RS; Winkfield K
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e1-e8. PubMed ID: 30396823
[TBL] [Abstract][Full Text] [Related]
55. Prolonged shedding of infectious viruses with haplotype switches of SARS-CoV-2 in an immunocompromised patient.
Shoji K; Suzuki A; Okamoto M; Tsinda EK; Sugawara N; Sasaki M; Nogami Y; Kobayashi M; Oshitani H; Yanai M
J Infect Chemother; 2022 Jul; 28(7):1001-1004. PubMed ID: 35430092
[TBL] [Abstract][Full Text] [Related]
56. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
[TBL] [Abstract][Full Text] [Related]
57. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
58. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
[No Abstract] [Full Text] [Related]
59. Isolation of SARS-CoV-2 in Viral Cell Culture in Immunocompromised Patients With Persistently Positive RT-PCR Results.
Sung A; Bailey AL; Stewart HB; McDonald D; Wallace MA; Peacock K; Miller C; Reske KA; O'Neil CA; Fraser VJ; Diamond MS; Burnham CD; Babcock HM; Kwon JH
Front Cell Infect Microbiol; 2022; 12():804175. PubMed ID: 35186791
[TBL] [Abstract][Full Text] [Related]
60. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
